Last reviewed · How we verify
RIMANTADINE HYDROCHLORIDE
At a glance
| Generic name | RIMANTADINE HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1993 |
Approved indications
Common side effects
- Insomnia
- Dizziness
- Headache
- Nervousness
- Fatigue
- Nausea
- Vomiting
- Anorexia
- Dry mouth
- Abdominal Pain
- Asthenia
- Impaired Concentration
Key clinical trials
- Prophylactic Efficacy of Relenza Against Influenza A and B
- A Pharmacokinetic Study on Co-administration of Tamiflu (Oseltamivir) and Rimantadine in Healthy Volunteers (PHASE1)
- Hepatitis C Rimantadine and Antiviral Combination Therapy
- Chart Review of Antivirals for Influenza in Infants
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RIMANTADINE HYDROCHLORIDE CI brief — competitive landscape report
- RIMANTADINE HYDROCHLORIDE updates RSS · CI watch RSS